TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02480907

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Workshop Group
Description: Workshop support group

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Internet-based support group
Description: Internet based support group with E-mail coaching
Study: NCT00397943

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK's candidate Mycobacterium tuberculosis vaccine 692342
Description: Intramuscular injection, 2 doses at 0, 1 month

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK's candidate Mycobacterium tuberculosis vaccine 692342
Description: Intramuscular injection, 2 doses at 0, 1 month

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Comparator vaccine with recombinant Mycobacterium tuberculosis antigen and adjuvant system
Description: Intramuscular injection, 2 doses at 0, 1 month

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Comparator vaccine with recombinant Mycobacterium tuberculosis antigen and physiological saline
Description: Intramuscular injection, 2 doses at 0, 1 month
Study: NCT03177915

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Description: median nerve hydro-dissection using 10 cc saline injection
Study: NCT02268487

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline
Description: Treatment
Study: NCT00397943

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Control vaccine with the adjuvant system.
Description: Intramuscular injection, 2 doses at 0, 1 month
Study: NCT03718975

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Successor of Phonak Audéo B90
Description: Successor of the most recent Receiver in the canal (RIC) Hearing aid form Phonak which will be fitted to the participants individual Hearing loss.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Phonak Audéo B90
Description: The Phonak Audéo B90 is the most recent Receiver-in-the-canal Hearing aid from Phonak which will be fitted to the participants individual Hearing loss.
Study: NCT03551028

Intervention type: DEVICE
Group type: OTHER
Intervention: HPV self collection
Description: The proposed community based participatory study aims to determine whether offering self-collection for HPV testing through the mobile mammography unit is an acceptable and feasible method to increase access to cervical cancer screening for under-screened women in Southwest Virginia.
Study: NCT03607734

Intervention type: DRUG
Group type: OTHER
Intervention: Amoxicillin
Description: A graded oral challenge test, using amoxicillin in syrup form, will be administered as follows:~* 50mg amoxicillin (10% total dose)~* 250mg amoxicillin (50% total dose)~* 200mg amoxicillin (remainder needed to complete a 500mg full dose) A 20 minute interval will separate each dose given, and participants will be observed throughout the test. They will be required to stay for one hour after the final dose has been administered. Fully trained staff and all equipment for emergency resuscitation will be immediately available.
Study: NCT03741881

Intervention type: OTHER
Intervention: No treatment given
Description: Participants are treated with their usual prescribed treatment, either given regularly as a prevention (prophylaxis) or when needed (on-demand).
Study: NCT02987660

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Topography Guided LASIK
Description: Corneal surgery for refractive error correction
Study: NCT03004014

Intervention type: OTHER
Group type: OTHER
Intervention: Sleep endoscopy during propofol induced sleep
Description: It will be performed a sleep endoscopy during drug induced sleep endoscopy
Study: NCT02987660

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Small Incision Lenticular Extraction
Description: Refractive surgical procedure for the correction of myopia with or without astigmatism

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WaveLight EX500 Excimer Laser System
Description: As used for corneal stroma ablation (refractive error correction). The treatment is intended to last the subject's lifetime.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: VisuMax Surgical Laser
Description: As used for lenticule creation/removal (refractive error correction). The treatment is intended to last the subject's lifetime.
Study: NCT01756976

Intervention type: DEVICE
Intervention: OrthoPat Advance
Description: The device will be used initially in hysterectomy procedures. After a confirmation of product quality, the device will be used in routine orthopedic procedures.
Study: NCT06298097

Intervention type: DEVICE
Group type: OTHER
Intervention: Connectivity measures
Description: Electroencephalography connectivity measures will be collected and compared in both stroke patients and healthy participants. Connectivity measures will be extracted using these devices: high-density electroencephalography (using either a 128-channel or a 256-channel system) and magnetic resonance imaging.

Intervention type: DEVICE
Group type: OTHER
Intervention: Connectivity measures
Description: Electroencephalography connectivity measures will be collected and compared in both stroke patients and healthy participants. Connectivity measures will be extracted using these devices: high-density electroencephalography (using either a 128-channel or a 256-channel system) and magnetic resonance imaging.
Study: NCT03110822

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib Oral Tablet [Jakafi]
Description: Ruxolitinib will be administered on days 1-28 of the treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib Oral Tablet [Jakafi]
Description: Ruxolitinib will be administered on days 1-28 of the treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib Oral Tablet [Jakafi]
Description: Ruxolitinib will be administered on days 1-28 of the treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib Oral Tablet [Jakafi]
Description: Ruxolitinib will be administered on days 1-28 of the treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide will be administered on Days 1-21 of the treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide will be administered on Days 1-21 of the treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide will be administered on Days 1-21 of the treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Methyl-prednisolone will be administered on Days 1-28 of the treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Methyl-prednisolone will be administered on Days 1-28 of the treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Methyl-prednisolone will be administered on Days 1-28 of the treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Methyl-prednisolone will be administered on Days 1-28 of the treatment cycle.
Study: NCT01754896

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mailing of FIT kit directly to patient
Description: Patient receives a mailed invitation to participate in CRC screening, with a FIT screening kit included.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mailing of FIT kit directly to patient
Description: Patient receives a mailed invitation to participate in CRC screening, with a FIT screening kit included.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mailed invitation to pick up lab requisition and then kit
Description: Patients receives a mailed invitation to visit their physician to discuss CRC screening. At that visit, they would receive a FIT laboratory requisition, which they will take to a local lab patient service centre to pick up a FIT kit.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mailed invitation to pick up lab requisition and then kit
Description: Patients receives a mailed invitation to visit their physician to discuss CRC screening. At that visit, they would receive a FIT laboratory requisition, which they will take to a local lab patient service centre to pick up a FIT kit.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mailing completed kits in for processing
Description: Patients mails completed kit in for processing using postage-paid reply envelope provided.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mailing completed kits in for processing
Description: Patients mails completed kit in for processing using postage-paid reply envelope provided.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dropping completed kits at lab for processing
Description: Patient takes completed FIT in to lab patient service centre for processing.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dropping completed kits at lab for processing
Description: Patient takes completed FIT in to lab patient service centre for processing.
Study: NCT02943551

Intervention type: OTHER
Group type: OTHER
Intervention: Online Tutorial
Description: For each group of practices, during the first month of intervention participation, study staff at Seattle Children's Research Institute will send each participating provider within a group/wedge, via email, a password to access the online tutorial. Participants will be asked to view the 40-minute tutorial at a time that is convenient for them but prior to the first webinar. Investigators will be able to track whether and how often participants access the online tutorial as a measure of engagement in the intervention. PROS will follow up, via email or phone, with providers who have not completed the tutorial within a three week timeframe.

Intervention type: OTHER
Group type: OTHER
Intervention: Webinars
Description: The first webinar, focused on making appropriate antibiotic choices for bacterial ARTIs, will be held at the beginning of month 2 of intervention participation, and the second webinar, focused on recommended communication practices during visits for ARTIs, will be held at the beginning of month 3 of intervention participation. Due to webinar faculty time constraints, we will establish dates/times for the webinar prior to recruitment. Providers will be given information on webinar dates in both the randomization email, as well as include the dates in the study box letter.~The webinars will be recorded to facilitate attendance for those who are unable to make the scheduled date/time. Included in the recording will be the presentation and any questions and answers from participants.

Intervention type: OTHER
Group type: OTHER
Intervention: Booster Sessions
Description: An online link to the first booster video vignette will be sent to practice participants via email at the beginning of month 5 of intervention participation for each group/wedge. The link will lead to a website in which the provider will need to create a user name and password to access the booster videos. Two additional booster vignettes will be made available for viewing at the beginning of months 7 and 9 of intervention participation.~For each of the three booster sessions, up to three reminders to complete viewing the video vignette will be sent over a 2-week period. The study team will be able to monitor whether participants access and complete the questions at the end of each vignette.
Study: NCT01728480

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT03106545

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liposome bupivacaine
Study: NCT03518749

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 1mA tDCS
Description: transcranial direct current stimulation with the intensity of 1mA

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 2mA tDCS
Description: transcranial direct current stimulation with the intensity of 2mA
Study: NCT03106545

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Liposome bupivacaine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposome bupivacaine
Study: NCT02177617

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botox injection
Description: Participants will receive a tailored dose of Botox to address their Cervical Dystonia symptoms

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botox injection
Description: Participants will receive a tailored dose of Botox to address their Cervical Dystonia symptoms

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical Therapy
Description: Participants will undergo physical therapy sessions with a physical therapist trained in movement disorders. Participants will be instructed to continue these exercises five times per week, and will be called weekly by the investigator to check progress.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial magnetic stimulation (TMS)
Description: For these tests, participants will sit in a chair that looks like one found at the dentist's office. A nerve stimulator will be placed on the wrist of the right hand to stimulate the median and ulnar nerves. The intensity of the nerve stimulator will be gradually increased until the right thumb begins to twitch. A magnetic coil will be placed on the scalp on the left side of the head, overlying the brain's motor cortex, to stimulate the brain's output to the muscles in the opposite hand. This procedure will be repeated using the left wrist and the right side of the head.
Study: NCT03518749

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive control training
Description: cognitive control training with the PASAT

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive control training
Description: cognitive control training with the PASAT

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Cognitive control training
Description: cognitive control training with the PASAT
Study: NCT02017600

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ND-420
Description: ND-420 50 mg/m2 on day1

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: After induction chemotherapy, participants will be receive right or left thoracotomy for curative resection by total or subtotal thoracic esophagectomy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: cisplatin 70 mg/m2 on day1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: fluorouracil 700 mg/m2 daily, day1 to day4
Study: NCT00075439

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gefitinib
Description: Given orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT01840995

Intervention type: PROCEDURE
Intervention: ultrasonographic measurement of optic nerve sheath diameter
Description: A thick layer of gel is applied on the upper closed eyelid. The linear 13- to 6-MHz ultrasound probe is then placed in the gel, without exerting pressure on the eye. Two measurements are taken for each optic nerve: one in the transverse plane, with the probe being horizontal, and one in the sagittal plane, with the probe being vertical. The final ONSD is the mean of these measurements.
Study: NCT03372889

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Patient educaiton materials - Print based
Description: Print (paper) based materials

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Patient educaiton materials - Media based
Description: Media (electronic) based materials
Study: NCT03584373

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac Oral Tablet [Toradol]
Description: Ketorolac is a prescribed NSAID with strong analgesic activity. Ketorolac will be administered post surgery to compare pain outcomes to that of Percocet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Acetaminophen is an over-the counter pain medication that will be administered post surgery to compare pain outcomes to that of Percocet.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone Acetaminophen
Description: Percocet is a prescribed opioid medication to manage pain. Percocet will be administered post surgery to compare pain outcomes to that of non-opioid analgesia.
Study: NCT01487577

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Description: Based on individual pharmacokinetics data, mycophenolate mofetil will be administered by continuous infusion to target a desired AUC exposure
Study: NCT03956355

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tapinarof
Description: Tapinarof cream, 1%, applied once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Cream
Description: Vehicle cream applied once daily
Study: NCT03709732

Intervention type: OTHER
Intervention: no intervention
Description: observational study

Intervention type: OTHER
Intervention: no intervention
Description: observational study

Intervention type: OTHER
Intervention: no intervention
Description: observational study
Study: NCT00673270

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludrocortisone
Description: 50 µg of fludrocortisone per os
Study: NCT02177617

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial magnetic stimulation (TMS)
Description: For these tests, participants will sit in a chair that looks like one found at the dentist's office. A nerve stimulator will be placed on the wrist of the right hand to stimulate the median and ulnar nerves. The intensity of the nerve stimulator will be gradually increased until the right thumb begins to twitch. A magnetic coil will be placed on the scalp on the left side of the head, overlying the brain's motor cortex, to stimulate the brain's output to the muscles in the opposite hand. This procedure will be repeated using the left wrist and the right side of the head.
Study: NCT03885934

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V114
Description: V114 15-valent PCV containing 13 serotypes present in Prevnar 13® (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) and 2 unique serotypes (22F and 33F) in each 0.5 mL IM administration

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V114
Description: V114 15-valent PCV containing 13 serotypes present in Prevnar 13® (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) and 2 unique serotypes (22F and 33F) in each 0.5 mL IM administration
Study: NCT02714543

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aloevera juice
Description: aloevera juice to drink twice daily for 3 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocortisone
Description: intralesional injection of hydrocortisone 100mg once a week for 6 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyaluronic Acid
Description: injection hyaluronic acid 1500IU once a week for 6 weeks
Study: NCT03885934

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V114
Description: V114 15-valent PCV containing 13 serotypes present in Prevnar 13® (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) and 2 unique serotypes (22F and 33F) in each 0.5 mL IM administration

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevnar 13®
Description: Prevnar 13® 13-valent PCV containing 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) in each 0.5 mL IM administration.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevnar 13®
Description: Prevnar 13® 13-valent PCV containing 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) in each 0.5 mL IM administration.
Study: NCT02943551

Intervention type: OTHER
Group type: OTHER
Intervention: Feedback Reports
Description: During the intervention phase, providers will also receive 6 audit and feedback reports given by parents.~The first report will have two parts:~* The first part will focus on the provider's overall antibiotic prescribing rates for all ARTIs (viral and bacterial) and rates of using second-line antibiotics for bacterial ARTIs.~* The second part will report the rates at which the provider uses the targeted communication practices as well as their average satisfaction scores.

Intervention type: OTHER
Group type: OTHER
Intervention: Parent Survey
Description: Throughout the study, parents at participating practice sites will be offered the opportunity to complete a DART Parent Survey after their child's visit.
Study: NCT03366844

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: checkpoint inhibitor

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: RT Boost
Description: The second dose of pembrolizumab will be given in conjunction with an RT boost, consisting of 8 Gy for 3 fractions.
Study: NCT04296136

Intervention type: OTHER
Intervention: Advance Care Planning Discussion
Description: Goals of care discussion with patient, documentation with electronic health record note and advance care planning billing. This will also include: pharmacy review of medications, case management review, and coding specialist review.
Study: NCT02612714

Intervention type: DRUG
Group type: OTHER
Intervention: Rosuvastatin
Description: All parameters were measured before statin treatment, after 6 months of statin treatment and 6 months after discontinuing statin treatment. Scores of the sexual health inventory for men (SHIM) were also evaluated.
Study: NCT03846362

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HSCT
Description: allogenic HSCT from 5-8 HLA-MM family donor as a first choice for patients with initial high risk of relapse and for patients with MRD2\>0,1% and initial intermediate risk
Study: NCT02463591

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beriplex
Description: Beriplex 50 IU/Kg i.v. , single dose.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Beriplex
Description: Beriplex 50 IU/Kg i.v. , single dose.
Study: NCT00673270

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Description: 50 mg of intravenous hydrocortisone
Study: NCT04133753

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Facilitator-Based Intervention
Description: Facilitators interact in person with patients, family, and clinicians both during and following the patient's ICU stay for 3 months. In-person contacts include visits to patients' homes and/or care facilities; phone contacts include calls to patients, families and clinicians. Patients and families have access to facilitators through phone and email. Facilitators may attend clinic visits with patients. In addition to checking directly with patients/families during regular contacts, facilitators also access the electronic health record to ensure they have accurate information about appointments and treatment plans and to document key points for the clinical team. Facilitators encourage referral to inpatient or outpatient palliative care services when needs are identified.